NasdaqGM:SIGA
NasdaqGM:SIGAPharmaceuticals

SIGA Technologies (SIGA) Is Down 21.0% After TPOXX Sales Drop and Third-Quarter Net Loss - Has The Bull Case Changed?

SIGA Technologies reported its third-quarter 2025 financial results this week, revealing a drop in quarterly revenue to US$2.62 million and a net loss of US$6.37 million compared to a profit in the same period last year. Despite strong nine-month performance, quarterly sales of its main antiviral treatment, TPOXX, declined sharply, increasing focus on the company’s reliance on government procurement and international regulatory progress. We’ll consider how the sharp third-quarter sales drop...